Abstract
HIV protease catalyzes the hydrolysis of specific peptide bonds of viral polyproteins, thus processing these polyproteins into their active components. These protein processing reactions are requisite for viral replication. Therefore, the HIV protease is an ideal target for the chemotherapeutic treatment of HIV disease (1–3). HIV protease is an aspartyl protease,and the aspartyl protease inhibitor, pepstatin, was one of the first identified inhibitors of HIV protease. More potent inhibitors have been designed and synthesized since, in fact, four protease inhibitors—saquinavir (Ro-31,8959), ritonavir (ABT-538), indinavir (L-735,524), and Nelfinavir (AG1343)—are effective in clinical trials to treat HIV disease (4–6) and recently were approved by the Food and Drug Administration for the chemotherapeutic treatment of HIV infections. Other protease inhibitors in clinical trials are VX-478 (141W94) and ABT-378. Notwithstanding these early successes, it is difficult to comply with these drug’s dosing regiments. Furthermore, viral resistance to individual inhibitors and cross-resistance to multiple inhibitors occur in vivo (7,8). Therefore, a medical need still exists for new HIV protease inhibitors with different resistance profiles.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Huff, J. R. (1991) HIV protease: A novel chemotherapeutic target for AIDS. J. Med. Chem. 34, 2305–2314.
Norbeck, D. W. and Kempf, D. J., (1991) in Annual Reports in Medicinal Chemistry (Bristol, J. A., ed.), Academic, San Diego, pp. 141–150.
Dark, P. L. and Huff, J. R. (1994) HIV protease as an inhibitor target of the treatment of AIDS. Adv. Pharmacol. 25, 399–454.
Jacobsen, H., Brun-Vezinet, F., Duncan, I., Hanggi, M., Ott, M., Vella, S., Weber, J., and Mous, J. (1994) Genotypic characterizations of HIV-1 from patients aftger prolonged treatment withproteinase inhibitor saquinavir, in III International Workshop on HIV Drug-Resistance, 3, p. 16.
Ho, D. D., Neumann, A. V., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995) Rapid turnover of plama virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126.
Wei, X., Ghosh, S. K., Taylor, M., E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S., and Shaw, G. M. (1995) Viral dynamics in human immunodeficiency virus type-1 infection. Nature 373, 117–122.
Richman, D. D. (1995) Protease uninhibited. Nature 374, 494.
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571.
Toth, M. V. and Marshall, G. R. (1990) A Simple continuous fluorometric assay for HIV protease. Int. J. Peptide Protein Res. 36, 544–550.
Maschera, B., Darby, G., Palú, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., and Furfine, E. S. (1996) Human immunodeficiency virus: Mutations in the protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271, 33,231–33,235.
Morrison, J. F. and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv. Enz. 61, 201–301.
Jordan, S. P., Zugau, J., Darke, P. L., and Kuo, L. C. (1992) Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration. J. Biol. Chem. 267, 20,028–20,032.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Furfine, E.S. (2000). Identifying and Characterizing HIV Protease Inhibitors. In: Kinchington, D., Schinazi, R.F. (eds) Antiviral Methods and Protocols. Methods in Molecular Medicine™, vol 24. Humana Press. https://doi.org/10.1385/1-59259-245-7:313
Download citation
DOI: https://doi.org/10.1385/1-59259-245-7:313
Publisher Name: Humana Press
Print ISBN: 978-0-89603-561-4
Online ISBN: 978-1-59259-245-6
eBook Packages: Springer Protocols